Clinical Trial

Terazosin Effect on Cardiac Changes in Early Parkinson's Disease

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Parkinson's disease (PD) is characterized by many non-motor symptoms that occur several years before the diagnosis, in particular idiopathic REM behavior disorder (iRBD), which is associated with autonomic impairment. The purpose of this study is to investigate the effect of treatment with the selective post-synaptic a1-adrenergic blocker terazosin on 123I-MIBG myocardial uptake in a population of subjects with defined pre-motor PD risks (i.e. hyposmia and RBD) and abnormal baseline 123I-MIBG uptake, with or without 123I-Ioflupane uptake abnormality or PD motor symptoms. Scintigraphic changes will be correlated to motor and non-motor severity of PD, measured by validated clinical scales and cardiac autonomic function tests.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-05-08; most recent amendment 2026-02-26.
Status change: Recruiting → Active, Not Recruiting 2026-02-26
Status change: Not Yet Recruiting → Recruiting 2020-11-02
Trial Details
NCT Number NCT04386317
Lead Sponsor Cedars-Sinai Medical Center
Conditions REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease, Symptomatic Parkinson Disease
Enrollment 15 participants
Start Date 2020-11-01
Primary Completion 2025-12-10 (estimated)
Study Completion 2026-03-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-02